# SonoThera

> SonoThera is a South San Francisco biotech developing an ultrasound-guided, nonviral platform for delivering genetic medicines. Instead of the viral vectors that dominate gene therapy, it uses focused ultrasound and injectable microbubbles - a process called sonoporation - to open transient pores in target cells and shuttle DNA or RNA payloads into specific organs. The pitch is delivery that is targeted, potentially redosable, and decoupled from the immune and manufacturing headaches of viruses. The company raised a $125M Series B in June 2026 and is pushing lead programs in Duchenne muscular dystrophy and polycystic kidney disease toward the clinic.

- **Founded:** 2022
- **Headquarters:** South San Francisco, California, United States
- **Founders:** Kenneth Greenberg (Co-Founder, President & CEO), Steve Feinstein (Co-Founder & Chief Scientific Officer), Michael H. Davidson (Co-Founder & Executive Chairman)
- **Team size:** 50 employees (LinkedIn lists 11-50)
- **Products:** RIPPLE ultrasound delivery platform, PORE payload engineering, Duchenne muscular dystrophy (DMD) program, ADPKD program
- **Notable:** Closed an oversubscribed $125M Series B in June 2026, led by Vida Ventures., Raised over $185M across Series A and Series B from top-tier and strategic pharma investors., Demonstrated preclinical targeted delivery across skeletal muscle, heart, liver, kidney, adipose tissue and brain.

## Products & services

- **RIPPLE ultrasound delivery platform** — Proprietary focused-ultrasound technology (Remote Induction of Pulsed Pressure Lateral to Energy) that, combined with injectable microbubbles, uses sonoporation to transiently open cell membranes and deliver genetic payloads to targeted organs.
- **PORE payload engineering** — Payload optimization and engineering approach for packaging DNA, RNA, gene editing and gene silencing constructs for nonviral, ultrasound-mediated delivery.
- **Duchenne muscular dystrophy (DMD) program** — Lead program delivering large payloads including full-length dystrophin to skeletal muscle and heart; first clinical trial expected in 2027.
- **ADPKD program** — Lead program targeting autosomal dominant polycystic kidney disease via ultrasound-guided delivery to the kidney.

## Achievements

- Closed an oversubscribed $125M Series B in June 2026, led by Vida Ventures.
- Raised over $185M across Series A and Series B from top-tier and strategic pharma investors.
- Demonstrated preclinical targeted delivery across skeletal muscle, heart, liver, kidney, adipose tissue and brain.
- Delivered large payloads including full-length dystrophin for Duchenne muscular dystrophy in preclinical models.
- Signed a research collaboration with Janssen Pharmaceuticals.
- Co-founded by the inventor of the first two FDA-approved ultrasound microbubble contrast agents.

## Latest updates

- **2026-06** — Closed oversubscribed $125M Series B led by Vida Ventures to advance DMD and ADPKD programs toward the clinic.
- **2025** — Established and trademarked the RIPPLE ultrasound delivery platform.
- **2024-11** — Presented preclinical data on ultrasound-mediated gene delivery to the heart at the American Heart Association Scientific Sessions.
- **2023** — Announced research collaboration with Janssen Pharmaceuticals and completed $60.75M Series A financing.

## Links

- Website: https://sonothera.com
- LinkedIn: http://www.linkedin.com/company/sonothera
- Twitter/X: https://x.com/SonotheraI41798
- Bluesky: https://bsky.app/profile/sonothera.bsky.social

---

Profile page: https://yespress.io/sonothera
Published by YesPress — https://yespress.io
Last updated: 2026-07-10